Anika Therapeutics Stock Analysis

ANIK Stock  USD 25.69  0.18  0.71%   
Anika Therapeutics is undervalued with Real Value of 27.0 and Target Price of 26.33. The main objective of Anika Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Anika Therapeutics is worth, separate from its market price. There are two main types of Anika Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Anika Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Anika Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Anika Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Anika Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Anika Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Anika Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Anika Stock Analysis Notes

About 94.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.75. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics has Price/Earnings To Growth (PEG) ratio of 2.23. The entity recorded a loss per share of 5.64. The firm had not issued any dividends in recent years. Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people. For more info on Anika Therapeutics please contact Charles Sherwood at 781 457 9000 or go to https://www.anika.com.

Anika Therapeutics Quarterly Total Revenue

42.97 Million

Anika Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Anika Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Anika Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 96.78 M.
Anika Therapeutics currently holds about 87.78 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01.
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: SG Americas Securities LLC Acquires 1341 Shares of Anika Therapeutics, Inc. - Defense World

Anika Therapeutics Upcoming and Recent Events

Earnings reports are used by Anika Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anika Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Anika Largest EPS Surprises

Earnings surprises can significantly impact Anika Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
1999-10-21
1999-09-300.014.0E-4-0.009696 
2008-07-22
2008-06-300.060.070.0116 
2021-03-04
2020-12-310.140.12-0.0214 
View All Earnings Estimates

Anika Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Anika Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anika Therapeutics backward and forwards among themselves. Anika Therapeutics' institutional investor refers to the entity that pools money to purchase Anika Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2023-12-31
318.9 K
State Street Corporation2023-12-31
309 K
Nuveen Asset Management, Llc2023-12-31
265.5 K
Arrowstreet Capital Limited Partnership2023-12-31
222.5 K
Invenomic Capital Management, Lp2023-12-31
210.3 K
Alta Fundamental Advisers Llc2023-12-31
192.5 K
D. E. Shaw & Co Lp2023-09-30
192.1 K
Goldman Sachs Group Inc2023-12-31
161.5 K
Northern Trust Corp2023-12-31
137.4 K
Trigran Investments Inc2023-12-31
2.1 M
Blackrock Inc2023-12-31
1.4 M
Note, although Anika Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Anika Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 378.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Anika Therapeutics's market, we take the total number of its shares issued and multiply it by Anika Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Anika Profitablity

Anika Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Anika Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Anika Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Anika Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Anika Therapeutics' profitability requires more research than a typical breakdown of Anika Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.5) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.57 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.57.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.32)(0.30)
Return On Capital Employed(0.11)(0.10)
Return On Assets(0.31)(0.29)
Return On Equity(0.39)(0.37)

Management Efficiency

Anika Therapeutics has return on total asset (ROA) of (0.0236) % which means that it has lost $0.0236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3321) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.3 this year. Return On Capital Employed is expected to rise to -0.1 this year. At this time, Anika Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 148 M.
Last ReportedProjected for Next Year
Book Value Per Share 14.48  15.21 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 13.65  14.33 
Enterprise Value Over EBITDA(25.70)(26.99)
Price Book Value Ratio 1.56  1.73 
Enterprise Value Multiple(25.70)(26.99)
Price Fair Value 1.56  1.73 
Enterprise Value511.9 M537.5 M
The analysis of Anika Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Anika Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Anika Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.751

Technical Drivers

As of the 18th of April 2024, Anika Therapeutics shows the Mean Deviation of 1.51, risk adjusted performance of 0.0823, and Downside Deviation of 1.84. Anika Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Anika Therapeutics, which can be compared to its peers. Please confirm Anika Therapeutics variance, as well as the relationship between the maximum drawdown and semi variance to decide if Anika Therapeutics is priced correctly, providing market reflects its regular price of 25.69 per share. Given that Anika Therapeutics has jensen alpha of 0.1743, we suggest you to validate Anika Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Anika Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Anika Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Anika Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Anika Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anika Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Anika Therapeutics Predictive Daily Indicators

Anika Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Anika Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Anika Therapeutics Corporate Filings

13A
5th of April 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
19th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
15th of March 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
13th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
12th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
6th of March 2024
An amendment to the original Schedule 13D filing
ViewVerify
8K
26th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
13th of February 2024
An amended filing to the original Schedule 13G
ViewVerify

Anika Therapeutics Forecast Models

Anika Therapeutics' time-series forecasting models are one of many Anika Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Anika Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Anika Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Anika Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Anika shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Anika Therapeutics. By using and applying Anika Stock analysis, traders can create a robust methodology for identifying Anika entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.51)(0.49)
Operating Profit Margin(0.15)(0.15)
Net Loss(0.50)(0.47)
Gross Profit Margin 0.62  0.45 

Current Anika Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Anika analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Anika analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
26.33Buy3Odds
Anika Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Anika analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Anika stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Anika Therapeutics, talking to its executives and customers, or listening to Anika conference calls.
Anika Analyst Advice Details

Anika Stock Analysis Indicators

Anika Therapeutics stock analysis indicators help investors evaluate how Anika Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Anika Therapeutics shares will generate the highest return on investment. By understating and applying Anika Therapeutics stock analysis, traders can identify Anika Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow86.3 M
Common Stock Shares Outstanding14.7 M
Total Stockholder Equity212.3 M
Tax Provision-3.9 M
Quarterly Earnings Growth Y O Y-0.505
Property Plant And Equipment Net75 M
Cash And Short Term Investments72.9 M
Cash72.9 M
Accounts Payable9.9 M
Net Debt-43.8 M
50 Day M A25.109
Total Current Liabilities31.1 M
Other Operating Expenses192.1 M
Non Current Assets Total107.3 M
Forward Price Earnings22.3214
Non Currrent Assets Other14 M
Stock Based Compensation15.2 M
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Anika Stock analysis

When running Anika Therapeutics' price analysis, check to measure Anika Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anika Therapeutics is operating at the current time. Most of Anika Therapeutics' value examination focuses on studying past and present price action to predict the probability of Anika Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anika Therapeutics' price. Additionally, you may evaluate how the addition of Anika Therapeutics to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Is Anika Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(5.64)
Revenue Per Share
11.372
Quarterly Revenue Growth
0.085
Return On Assets
(0.02)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.